China Resources Pharmaceutical Group Dividendos y recompras
Dividendo controles de criterios 3/6
China Resources Pharmaceutical Group es una empresa que paga dividendos con una rentabilidad actual de 3.44% que está bien cubierta por los beneficios.
Información clave
3.4%
Rentabilidad por dividendo
5.0%
Rendimiento de la recompra
| Rendimiento total para el accionista | 8.4% |
| Rendimiento futuro de los dividendos | 4.0% |
| Crecimiento de los dividendos | 13.6% |
| Próxima fecha de pago de dividendos | n/a |
| Fecha ex dividendo | n/a |
| Dividendo por acción | HK$0.184 |
| Ratio de pago | 39% |
Últimas actualizaciones de dividendos y recompras
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01
China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14Recent updates
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up
Oct 07Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: Aunque el pago de dividendos se ha mantenido estable, 3320 lleva pagando dividendos menos de 10 años.
Dividendo creciente: El pago de dividendos de 3320 ha aumentado, pero la empresa sólo ha pagado dividendos durante 8 años.
Rentabilidad por dividendo vs. Mercado
| Rentabilidad por dividendo de China Resources Pharmaceutical Group vs. Mercado |
|---|
| Segmento | Rentabilidad por dividendo |
|---|---|
| Empresa (3320) | 3.4% |
| Suelo de mercado 25% (HK) | 3.3% |
| Techo de mercado 25% (HK) | 8.1% |
| Media de la industria (Pharmaceuticals) | 3.8% |
| Analista de previsiones (3320) (hasta 3 años) | 4.0% |
Dividendo destacado: El dividendo de 3320(3.44%) es más alto que el 25% inferior de los pagadores de dividendos del mercado Hong Kong (3.3%).
Alto dividendo: El (3.44%) del dividendo de 3320 es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado Hong Kong (8.06%).
Pago de beneficios a los accionistas
Cobertura de los beneficios: Con su razonablemente bajo ratio de pago (39.4%), los pagos de dividendos de 3320 están bien cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: Con su bajo ratio de pago en efectivo (6.8%), los pagos de dividendos de 3320 están totalmente cubiertos por los flujos de caja.